Related Experiment Video
Updated: May 7, 2026
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
Published on: September 21, 2021
Is MS an inflammatory or primary degenerative disease?
1Department of Clinical Neuroimmunology, University School of Medicine, Poznan, Poland, jlosy@amp.edu.pl.
Abstract:
Multiple sclerosis (MS) is characterized by multiple areas of inflammation, demyelination and neurodegeneration. Multiple molecular and cellular components mediate neuroinflammation in MS. They involve: adhesion molecules, chemokines, cytokines, matalloproteases and the following cells: CD4+ T cells, CD8+ T cells, B cells, microglia and macrophages. Infiltrating Th1 CD4+ T cells secrete proinflammatory cytokines. They stimulate the release of chemokines, expression of adhesion molecules and can be factors that cause damage to the myelin sheath and axons. Chemokines stimulate integrin activation, mediate leukocyte locomotion on endothelial cells and participate in transendothelial migration. CD8+ cells can directly damage axons. B cells are involved in the production of antibodies which can participate in demyelination. B cells can also function as antigen presenting cells and contribute to T cell activation. Neuroinflammation is not only present in relapsing-remitting MS, but also in the secondary and primary progressive forms of the disease. The association between inflammation consisting of T cells, B cells, plasma cells and macrophages and axonal injury exists in MS patients including the progressive forms of the disease. The above association does not exclude the possibility that neurodegeneration can exist independently from inflammation. Very little inflammation is seen in cortical MS plaques. Anti-inflammatory therapies with different mode of action change the course of MS. Anti-inflammatory and immunomodulatory treatments are beneficial in the early relapsing stage of MS, but these treatments are ineffective in secondary progressive and primary progressive MS. In the stage of progressive MS, inflammation becomes trapped behind a closed or repaired blood-brain barrier. In such a situation current immunomodulatory, immunosuppressive or anti-inflammatory treatments might not reach this inflammatory process to exert a beneficial effect.
Insights
Multiple sclerosis (MS) involves inflammation, demyelination, and neurodegeneration mediated by various cells and molecules. While anti-inflammatory treatments help early MS, they are less effective in progressive stages due to the blood-brain barrier.
Area of Science:
- Neuroimmunology
- Neurology
- Pathophysiology of Multiple Sclerosis
Background:
- Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
- Neuroinflammation in MS involves a complex interplay of molecular and cellular components, including T cells, B cells, microglia, and macrophages.
- Inflammation, demyelination, and neurodegeneration are key pathological hallmarks of MS, present across its various forms.
Purpose of the Study:
- To elucidate the multifaceted role of neuroinflammation in the pathogenesis of multiple sclerosis.
- To examine the contribution of various immune cells and molecules to MS pathology.
- To evaluate the efficacy of current anti-inflammatory and immunomodulatory therapies in different stages of MS.
Main Methods:
- Review of molecular and cellular mechanisms underlying neuroinflammation in MS.
- Analysis of the involvement of immune cells (CD4+ T cells, CD8+ T cells, B cells, microglia, macrophages) in MS pathogenesis.
- Assessment of the impact of inflammation on myelin sheath and axonal integrity.
- Evaluation of the effectiveness of anti-inflammatory and immunomodulatory treatments in different MS disease courses.
Main Results:
- Neuroinflammation in MS is mediated by cytokines, chemokines, adhesion molecules, and immune cells.
- CD4+ T cells, CD8+ T cells, and B cells play critical roles in driving inflammation and direct tissue damage.
- While anti-inflammatory therapies are effective in relapsing-remitting MS, their efficacy diminishes in progressive forms due to the blood-brain barrier.
- Inflammation can persist in progressive MS, but may be less accessible to current treatments.
Conclusions:
- Neuroinflammation is a central feature of multiple sclerosis, contributing to demyelination and neurodegeneration.
- The effectiveness of immunomodulatory therapies is stage-dependent, highlighting the need for novel therapeutic strategies for progressive MS.
- Understanding the dynamics of neuroinflammation and the blood-brain barrier is crucial for developing more effective treatments for all MS patients.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
01:27Degenerative Disc Disease I: Introduction
01:23Degenerative Disc Disease ll: Pathophysiology
01:25Inflammatory Bowel Disease III: Crohn's Disease
01:25Secondary Spinal Cord Injury llI: Pathophysiology
01:12Chronic Inflammation: Introduction